Shree Ganesh [SGRL] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison

Shree Ganesh

BSE
Loading...

Aarti Drugs

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Shree Ganesh wins in 8 metrics, Aarti Drugs wins in 11 metrics, with 0 ties. Aarti Drugs appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricShree GaneshAarti DrugsBetter
P/E Ratio (TTM)30.8423.66Aarti Drugs
Price-to-Book Ratio4.653.26Aarti Drugs
Debt-to-Equity Ratio26.4444.92Shree Ganesh
PEG Ratio-1.190.37Shree Ganesh
EV/EBITDA17.5817.07Aarti Drugs
Profit Margin (TTM)20.16%7.80%Shree Ganesh
Operating Margin (TTM)19.77%10.11%Shree Ganesh
EBITDA Margin (TTM)19.77%10.11%Shree Ganesh
Return on Equity15.89%12.28%Shree Ganesh
Return on Assets (TTM)12.02%6.53%Shree Ganesh
Free Cash Flow (TTM)$74.69M$674.22MAarti Drugs
Dividend YieldN/A0.22%N/A
1-Year Return-38.00%-4.79%Aarti Drugs
Price-to-Sales Ratio (TTM)6.221.84Aarti Drugs
Enterprise Value$6.85B$50.47BAarti Drugs
EV/Revenue Ratio6.322.08Aarti Drugs
Gross Profit Margin (TTM)64.62%36.77%Shree Ganesh
Revenue per Share (TTM)$84$265Aarti Drugs
Earnings per Share (Diluted)$17.03$20.63Aarti Drugs
Beta (Stock Volatility)0.200.12Aarti Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Shree Ganesh vs Aarti Drugs Stock Performance Analysis

Loading Price Chart...

Shree Ganesh
Aarti Drugs
Shree Ganesh Stock Overview | Aarti Drugs Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Shree Ganesh-3.10%-2.27%-14.23%-10.95%-31.40%-22.63%
Aarti Drugs0.73%4.61%0.24%1.59%41.06%7.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Shree Ganesh-38.00%112.42%294.53%1,442.27%1,442.27%1,442.27%
Aarti Drugs-4.79%-0.89%-50.06%219.30%2,690.01%2,872.19%

News Based Sentiment: Shree Ganesh vs Aarti Drugs

Shree Ganesh

News based Sentiment: NEGATIVE

September brought disappointing financial results for Shree Ganesh Remedies, with a significant decline in net profit. Coupled with leadership changes and a falling stock price, the month paints a concerning picture for investors, suggesting potential challenges ahead despite a discounted valuation compared to peers.

View Shree Ganesh News Sentiment Analysis

Aarti Drugs

News based Sentiment: POSITIVE

Aarti Drugs reported substantial profit growth in both Q1FY26 and FY2025, coupled with increased institutional interest from Mutual Funds. While shareholding changes and recent price volatility exist, the overall narrative points towards a strengthening investment case.

View Aarti Drugs News Sentiment Analysis

Performance & Financial Health Analysis: Shree Ganesh vs Aarti Drugs

MetricSGRLAARTIDRUGS
Market Information
Market Cap i₹6.85B₹44.55B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i6,495201,942
90 Day Avg. Volume i4,949187,563
Last Close₹508.95₹491.60
52 Week Range₹494.95 - ₹950.00₹312.00 - ₹564.05
% from 52W High-46.43%-12.84%
All-Time High₹950.05 (Jul 22, 2024)₹1,026.95 (Oct 05, 2020)
% from All-Time High-46.43%-52.13%
Growth Metrics
Quarterly Revenue Growth-0.01%0.06%
Quarterly Earnings Growth-0.26%0.62%
Financial Health
Profit Margin (TTM) i0.20%0.08%
Operating Margin (TTM) i0.20%0.10%
Return on Equity (TTM) i0.16%0.12%
Debt to Equity (MRQ) i26.4444.92
Cash & Liquidity
Book Value per Share (MRQ)₹113.00₹149.84
Cash per Share (MRQ)₹22.01₹2.48
Operating Cash Flow (TTM) i₹337.14M₹2.83B
Levered Free Cash Flow (TTM) i₹230.68M₹1.68B
Dividends
Last 12-Month Dividend Yield iN/A0.22%
Last 12-Month Dividend i₹0.00₹1.00

Valuation & Enterprise Metrics Analysis: Shree Ganesh vs Aarti Drugs

MetricSGRLAARTIDRUGS
Price Ratios
P/E Ratio (TTM) i30.8423.66
Forward P/E iN/A15.02
PEG Ratio i-1.190.37
Price to Sales (TTM) i6.221.84
Price to Book (MRQ) i4.653.26
Market Capitalization
Market Capitalization i₹6.85B₹44.55B
Enterprise Value i₹6.85B₹50.47B
Enterprise Value Metrics
Enterprise to Revenue i6.322.08
Enterprise to EBITDA i17.5817.07
Risk & Other Metrics
Beta i0.200.12
Book Value per Share (MRQ) i₹113.00₹149.84

Financial Statements Comparison: Shree Ganesh vs Aarti Drugs

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)SGRLAARTIDRUGS
Revenue/Sales i₹246.68M₹5.91B
Cost of Goods Sold i₹87.28M₹3.73B
Gross Profit i₹159.40M₹2.17B
Research & Development iN/AN/A
Operating Income (EBIT) i₹48.77M₹593.60M
EBITDA i₹79.58M₹743.90M
Pre-Tax Income i₹45.98M₹511.10M
Income Tax i₹11.53M₹-28.60M
Net Income (Profit) i₹34.45M₹539.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)SGRLAARTIDRUGS
Cash & Equivalents i₹99.43M₹45.77M
Total Current Assets i₹775.75M₹13.38B
Total Current Liabilities i₹161.82M₹8.37B
Long-Term Debt i₹296.08M₹2.86B
Total Shareholders Equity i₹1.45B₹13.69B
Retained Earnings i₹1.10B₹12.40B
Property, Plant & Equipment i₹31.57M₹27.03M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)SGRLAARTIDRUGS
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSGRLAARTIDRUGS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i6,495201,942
Average Daily Volume (90 Day) i4,949187,563
Shares Outstanding i12.84M91.27M
Float Shares i2.20M39.04M
% Held by Insiders i0.76%0.60%
% Held by Institutions i0.00%0.11%

Dividend Analysis & Yield Comparison: Shree Ganesh vs Aarti Drugs

MetricSGRLAARTIDRUGS
Last 12-Month Dividend i₹0.00₹1.00
Last 12-Month Dividend Yield iN/A0.22%
3-Year Avg Annual Dividend i₹0.33₹1.00
3-Year Avg Dividend Yield i0.15%0.23%
3-Year Total Dividends i₹1.00₹3.00
Ex-Dividend DateSep 07, 2023Feb 04, 2025